Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CHKA | P35790 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.46 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL27830331 | 0.93 | SIGMAR1 (0.46) | CA2CA12CA1CA9CHKA | |
| Thiophene SCHEMBL28205716 | 0.86 | CA2 (0.42) | CA2CA12CA1CA9CHKA | |
| SCHEMBL27645872 | 0.86 | — | — | |
| Benzamide SCHEMBL1474746 | 0.79 | SIGMAR1 (0.58) | SIGMAR1POLBRXFP1 | |
| SCHEMBL5423303 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL277853 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| SCHEMBL2872323 | 0.78 | CA2 (0.48) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL17397450 | 0.76 | CA2 (0.46) | CA2CA12CA1CA9CHKA | |
| Formamide SCHEMBL28191106 | 0.76 | CA2 (0.42) | CA2CA12CA1CA9CHKA | |
| SCHEMBL7289777 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105646445-A | 2-amino quinazolinone compound synthesis process | 吕艳 | 2016-06-08 | — | — | CN | claimed |
| CN-105051013-A | Laquinimod sodium crystals and improved process for their manufacture | TEVA PHARMA | 2015-11-11 | — | — | CN | claimed |
| CN-102489165-B | Preparation method of ultrathin high network structural nanofiltration composite membrane | UNIV ZHEJIANG | 2013-08-28 | — | — | CN | claimed |
| US-8232312-B2 | Substituted arylsulphonylglycines, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | claimed |
| US-8211923-B2 | Substituted arylsulfonylaminomethylphosphonic acid derivatives, their preparation and their use in the treatment of type I and II diabetes mellitus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-03 | — | — | US | claimed |
| CN-102489165-A | Preparation method of ultrathin high network structural nanofiltration composite membrane | UNIV ZHEJIANG | 2012-06-13 | — | — | CN | claimed |
| EP-2125718-B1 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2010-09-15 | — | — | EP | claimed |
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | claimed |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-27 | — | — | US | claimed |
| EP-2185572-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2010-05-19 | — | — | EP | claimed |
| EP-2125718-A2 | NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-02 | — | — | EP | claimed |
| WO-2009016119-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-05 | — | — | WO | claimed |
| WO-2008113760-A2 | ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-25 | — | — | WO | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| US-4767768-A | ANTITHROMBIC, HYPOTENSIVE; OXIME-SUBSTITUTED | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-08-30 | — | — | US | claimed |
| EP-0113106-B1 | NEW NITRO ALIPHATIC COMPOUNDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| EP-0113106-A1 | New nitro aliphatic compounds, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-11 | — | — | EP | claimed |
| CN-108409731-B | Chiral resolution of aryl-substituted 1H-pyridine [3,4-b ] indole-3-carboxylic acid methyl ester | 西华大学 | 2020-11-20 | — | — | CN | disclosed |
| EP-0113106-B1 | NEW NITRO ALIPHATIC COMPOUNDS, PROCESS FOR PREPARATION THEREOF AND USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0113106-A1 | New nitro aliphatic compounds, process for preparation thereof and use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210595-A1 | SUBSTITUTED ARYLSULFONYLAMINOMETHYLPHOSPHONIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF TYPE I AND II DIABETES MELLITUS | G6PC1, PYGL, PPP1CA | CA2 846/4885CA12 3467/4885CA1 2382/4885 |
| US-20100130557-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | CA2 2322/4885CA12 4419/4885CA1 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.